Virobay Inc.
1490 O’Brien Drive, Suite G
1490 O’Brien Drive, Suite G
Menlo Park
California
94025
Tel: 1-650-833-5700
Fax: 1-650-833-6892
Website: http://www.virobayinc.com/
Email: info@virobayinc.com
11 articles about Virobay Inc.
-
Virobay Inc. To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society for Neuroscience Annual Meeting
11/14/2014
-
TPG-Backed Biotech Virobay Inc. Withdraws $50 Million IPO
11/3/2014
-
AbbVie-Backed Virobay Inc. Lines Up $50 Million IPO
9/11/2014
-
Virobay Inc. Completes $8 Million Series B Preferred Stock Financing
7/16/2014
-
Menlo Park's Virobay Inc. Completes $8 Million Series B Funding Round
7/16/2014
-
Virobay Inc. Announces The Appointment Of James Welch As Chief Financial Officer
6/25/2014
-
Virobay Inc. Appoints Thomas J. Dietz, Ph.D. To The Virobay Board Of Directors
2/25/2014
-
Virobay Inc. Initiates a Phase 1 Trial of VBY-036, a Compound Intended for the Treatment of Neuropathic Pain
5/23/2013
-
Virobay Inc. and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3/18/2013
-
LEO Pharma In-Licenses Promising Compound From Virobay Inc. for Oral Treatment of Psoriasis
1/9/2012
-
Virobay Inc.'s Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
11/15/2011